VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $293.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $222.50M, a 33.55% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $70.50M, a 46.57% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$664.50M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $332.90M, a 95.13% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$116.90M, a 154.91% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $212.90M, a 50.42% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $429.40M, a 20.85% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $542.50M, a 77.64% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $222.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $293.00M 10-Q · filed 2026-08-04 | -$371.50M derived: sum of 3 quarters · filed 2026-08-04 | -$38.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $70.50M 10-Q · filed 2026-05-05 | -$594.00M derived: sum of 2 quarters · filed 2026-05-05 | -$261.10M derived: sum of 3 quarters · filed 2026-05-05 | -$94.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$664.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$331.60M derived: sum of 2 quarters · filed 2026-02-13 | -$165.00M derived: sum of 3 quarters · filed 2026-08-04 | -$116.90M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $332.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $499.50M derived: sum of 2 quarters · filed 2026-08-04 | $547.60M 10-Q · filed 2025-11-04 | $227.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $166.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $214.70M 10-Q · filed 2026-08-04 | -$105.40M derived: sum of 3 quarters · filed 2026-08-04 | $65.20M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $48.10M 10-Q · filed 2026-05-05 | -$272.00M derived: sum of 2 quarters · filed 2026-05-05 | -$101.40M derived: sum of 3 quarters · filed 2026-05-05 | $66.90M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$320.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$149.50M derived: sum of 2 quarters · filed 2026-02-13 | $18.80M derived: sum of 3 quarters · filed 2026-02-13 | $212.90M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $170.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $338.90M derived: sum of 2 quarters · filed 2025-11-04 | $533.00M 10-Q · filed 2025-11-04 | $176.30M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $168.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $362.40M 10-Q · filed 2025-08-05 | $5.70M derived: sum of 3 quarters · filed 2026-02-13 | $374.40M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $194.10M 10-Q · filed 2025-05-06 | -$162.60M derived: sum of 2 quarters · filed 2026-02-13 | $206.10M derived: sum of 3 quarters · filed 2026-02-13 | $482.80M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | -$356.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $12.00M derived: sum of 2 quarters · filed 2026-02-13 | $288.70M derived: sum of 3 quarters · filed 2026-02-13 | $429.40M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $368.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $645.40M derived: sum of 2 quarters · filed 2024-11-05 | $786.10M 10-Q · filed 2024-11-05 | $348.30M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $276.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $417.40M 10-Q · filed 2024-08-02 | -$20.40M derived: sum of 3 quarters · filed 2025-02-13 | $412.80M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $140.70M 10-Q · filed 2024-05-07 | -$297.10M derived: sum of 2 quarters · filed 2025-02-13 | $136.10M derived: sum of 3 quarters · filed 2025-02-13 | $621.60M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | -$437.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$4.60M derived: sum of 2 quarters · filed 2025-02-13 | $480.90M derived: sum of 3 quarters · filed 2025-02-13 | $542.50M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $433.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $918.70M derived: sum of 2 quarters · filed 2023-11-07 | $980.30M 10-Q · filed 2023-11-07 | $1.03B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $485.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $547.10M 10-Q · filed 2023-08-02 | $598.30M derived: sum of 3 quarters · filed 2024-02-15 | $745.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $61.60M 10-Q · filed 2023-05-02 | $112.80M derived: sum of 2 quarters · filed 2024-02-15 | $259.50M derived: sum of 3 quarters · filed 2024-02-15 | $214.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $51.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $197.90M derived: sum of 2 quarters · filed 2024-02-15 | $152.40M derived: sum of 3 quarters · filed 2024-02-15 | $305.40M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $146.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $101.20M derived: sum of 2 quarters · filed 2022-10-28 | $254.20M 10-Q · filed 2022-10-28 | $254.16M 10-Q · filed 2021-11-03 | -$74.68M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | -$45.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $107.50M 10-Q · filed 2022-08-05 | $107.53M 10-Q · filed 2021-07-30 | -$221.38M derived: sum of 3 quarters · filed 2023-02-10 | -$140.15M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | $153.00M 10-Q · filed 2022-05-06 | $152.98M 10-Q · filed 2021-04-30 | -$175.88M derived: sum of 2 quarters · filed 2023-02-10 | -$94.65M derived: sum of 3 quarters · filed 2023-02-10 | $121.39M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | -$328.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | -$247.65M derived: sum of 2 quarters · filed 2023-02-10 | -$31.61M derived: sum of 3 quarters · filed 2023-02-10 | $122.20M 10-K · filed 2023-02-10 | ||||
| 2020-09-30 | $81.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $297.27M derived: sum of 2 quarters · filed 2021-11-03 | $451.08M 10-Q · filed 2021-11-03 | $368.29M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $216.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $369.85M 10-Q · filed 2021-07-30 | $287.05M derived: sum of 3 quarters · filed 2022-02-09 | $428.78M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $153.81M 10-Q · filed 2021-04-30 | $71.02M derived: sum of 2 quarters · filed 2022-02-09 | $212.75M derived: sum of 3 quarters · filed 2022-02-09 | $353.99M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | -$82.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $58.93M derived: sum of 2 quarters · filed 2022-02-09 | $200.18M derived: sum of 3 quarters · filed 2022-02-09 | $172.90M 10-K · filed 2022-02-09 | ||||
| 2019-09-30 | $141.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $282.98M derived: sum of 2 quarters · filed 2020-10-30 | $255.70M 10-Q · filed 2020-10-30 | $283.68M derived: sum of 4 quarters · filed 2020-10-30 | ||||
| 2019-06-30 | $141.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $113.97M 10-Q · filed 2020-07-31 | $141.94M derived: sum of 3 quarters · filed 2020-07-31 | $208.52M derived: sum of 4 quarters · filed 2020-07-31 | ||||
| 2019-03-31 | -$27.28M 10-Q · filed 2020-05-01 | -$38.42M 10-Q · filed 2019-05-01 | $697.00K derived: sum of 2 quarters · filed 2020-05-01 | $67.27M derived: sum of 3 quarters · filed 2020-05-01 | $199.81M derived: sum of 4 quarters · filed 2020-05-01 | |||
| 2018-12-31 | $27.98M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $94.55M derived: sum of 2 quarters · filed 2019-10-31 | $227.09M derived: sum of 3 quarters · filed 2019-10-31 | $195.62M 10-K · filed 2019-02-13 | ||||
| 2018-09-30 | $66.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $199.12M derived: sum of 2 quarters · filed 2019-10-31 | $167.65M 10-Q · filed 2019-10-31 | $199.64M 10-Q · filed 2018-10-25 | $95.50M derived: sum of 4 quarters · filed 2019-10-31 | |||
| 2018-06-30 | $132.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $101.07M 10-Q · filed 2019-08-01 | $126.65M 10-Q · filed 2018-07-26 | $28.93M derived: sum of 3 quarters · filed 2019-08-01 | $95.02M derived: sum of 4 quarters · filed 2019-08-01 | |||
| 2018-03-31 | -$31.47M 10-Q · filed 2019-05-01 | $7.35M 10-Q · filed 2018-04-27 | -$103.61M derived: sum of 2 quarters · filed 2019-05-01 | -$37.52M derived: sum of 3 quarters · filed 2019-05-01 | $54.33M derived: sum of 4 quarters · filed 2019-05-01 | |||
| 2017-12-31 | -$72.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$6.05M derived: sum of 2 quarters · filed 2019-02-13 | $85.80M derived: sum of 3 quarters · filed 2019-02-13 | $75.33M 10-K · filed 2019-02-13 | $246.22M 10-K · filed 2018-02-15 | |||
| 2017-09-30 | $66.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $157.94M derived: sum of 2 quarters · filed 2018-10-25 | $147.48M 10-Q · filed 2018-10-25 | $148.10M 10-Q · filed 2017-10-30 | $115.79M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-06-30 | $91.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $81.39M 10-Q · filed 2018-07-26 | $83.64M 10-Q · filed 2017-07-28 | $49.70M derived: sum of 3 quarters · filed 2019-02-13 | $90.38M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-03-31 | -$10.46M 10-Q · filed 2018-04-27 | -$9.93M 10-Q · filed 2017-04-28 | -$42.15M derived: sum of 2 quarters · filed 2019-02-13 | -$1.47M derived: sum of 3 quarters · filed 2019-02-13 | $13.89M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2016-12-31 | -$31.69M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $9.00M derived: sum of 2 quarters · filed 2019-02-13 | $24.36M derived: sum of 3 quarters · filed 2019-02-13 | -$5.57M 10-K · filed 2019-02-13 | $88.65M 10-K · filed 2017-02-23 | |||
| 2016-09-30 | $40.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $56.04M derived: sum of 2 quarters · filed 2017-10-30 | $26.12M 10-Q · filed 2017-10-30 | $83.70M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | $15.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$14.56M 10-Q · filed 2017-07-28 | $43.02M derived: sum of 3 quarters · filed 2018-02-15 | $80.09M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-03-31 | -$29.92M 10-Q · filed 2017-04-28 | $27.66M derived: sum of 2 quarters · filed 2018-02-15 | $64.73M derived: sum of 3 quarters · filed 2018-02-15 | $93.75M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2015-12-31 | $57.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $94.65M derived: sum of 2 quarters · filed 2018-02-15 | $123.67M derived: sum of 3 quarters · filed 2018-02-15 | $102.75M 10-K · filed 2018-02-15 | ||||
| 2015-09-30 | $37.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $66.08M derived: sum of 2 quarters · filed 2016-10-31 | $45.16M 10-Q · filed 2016-10-31 | $90.32M 10-Q · filed 2015-10-30 | -$30.23M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-06-30 | $29.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $8.10M 10-Q · filed 2016-08-01 | $38.21M 10-Q · filed 2015-08-04 | -$67.30M derived: sum of 3 quarters · filed 2017-02-23 | -$45.63M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-31 | -$20.92M 10-Q · filed 2016-05-03 | -$5.87M 10-Q · filed 2015-05-04 | -$96.31M derived: sum of 2 quarters · filed 2017-02-23 | -$74.64M derived: sum of 3 quarters · filed 2017-02-23 | -$70.57M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | -$75.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$53.72M derived: sum of 2 quarters · filed 2017-02-23 | -$49.65M derived: sum of 3 quarters · filed 2017-02-23 | -$63.18M 10-K · filed 2017-02-23 | -$3.27M 10-K · filed 2015-02-13 | |||
| 2014-09-30 | $21.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $25.75M derived: sum of 2 quarters · filed 2015-10-30 | $12.21M 10-Q · filed 2015-10-30 | $20.67M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-06-30 | $4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | -$9.46M 10-Q · filed 2015-08-04 | -$1.00M derived: sum of 3 quarters · filed 2016-02-16 | $20.55M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-03-31 | -$13.54M 10-Q · filed 2015-05-04 | -$5.08M derived: sum of 2 quarters · filed 2016-02-16 | $16.48M derived: sum of 3 quarters · filed 2016-02-16 | -$2.14M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2013-12-31 | $8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $30.01M derived: sum of 2 quarters · filed 2016-02-16 | $11.39M derived: sum of 3 quarters · filed 2016-02-16 | $34.63M 10-K · filed 2016-02-16 | $43.73M 10-K · filed 2014-02-11 | |||
| 2013-09-30 | $21.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $2.94M derived: sum of 2 quarters · filed 2014-11-06 | $26.17M 10-Q · filed 2014-11-06 | $32.87M 10-Q · filed 2013-11-07 | $43.38M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-06-30 | -$18.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $4.62M 10-Q · filed 2014-07-31 | $11.32M 10-Q · filed 2013-08-02 | $21.82M derived: sum of 3 quarters · filed 2015-02-13 | $24.54M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-03-31 | $23.24M 10-Q · filed 2014-05-05 | $40.44M derived: sum of 2 quarters · filed 2015-02-13 | $43.16M derived: sum of 3 quarters · filed 2015-02-13 | $68.24M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2012-12-31 | $17.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $19.92M derived: sum of 2 quarters · filed 2015-02-13 | $45.00M derived: sum of 3 quarters · filed 2015-02-13 | $29.23M 10-K · filed 2015-02-13 | ||||
| 2012-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $27.80M derived: sum of 2 quarters · filed 2013-11-07 | $12.03M 10-Q · filed 2013-11-07 | $20.23M 10-Q · filed 2012-11-06 | $34.15M derived: sum of 4 quarters · filed 2014-02-11 | |||
| 2012-06-30 | $25.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $9.31M 10-Q · filed 2013-08-02 | $31.43M derived: sum of 3 quarters · filed 2014-02-11 | $125.14M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | -$15.77M 10-Q · filed 2013-05-08 | -$7.25M 10-Q · filed 2012-05-10 | $6.35M derived: sum of 2 quarters · filed 2014-02-11 | $100.06M derived: sum of 3 quarters · filed 2014-02-11 | $123.73M derived: sum of 4 quarters · filed 2014-02-11 | |||
| 2011-12-31 | $22.12M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $115.83M derived: sum of 2 quarters · filed 2014-02-11 | $139.50M derived: sum of 3 quarters · filed 2014-02-11 | $116.82M 10-K · filed 2014-02-11 | $116.92M 10-K · filed 2012-02-22 | |||
| 2011-09-30 | $93.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $117.38M derived: sum of 2 quarters · filed 2012-11-06 | $94.70M 10-Q · filed 2012-11-06 | $91.47M 10-Q · filed 2011-11-03 | $101.86M derived: sum of 4 quarters · filed 2013-03-01 | |||
| 2011-06-30 | $23.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $995.00K 10-Q · filed 2012-08-08 | $8.15M derived: sum of 3 quarters · filed 2013-03-01 | |||||
| 2011-03-31 | -$22.68M 10-Q · filed 2012-05-10 | -$15.53M derived: sum of 2 quarters · filed 2013-03-01 | ||||||
| 2010-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $11.21M 10-K · filed 2013-03-01 | $8.18M 10-K · filed 2012-02-22 | |||||
| 2010-09-30 | $4.06M 10-Q · filed 2011-11-03 | |||||||
| 2009-12-31 | $8.92M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |